Some of the most significant changes in healthcare reform are being led by oncologists, especially as innovation and team-based collaboration are increasingly becoming the standard in cancer care delivery.
Some of the most significant changes in healthcare reform are being led by oncologists, especially as innovation and team-based collaboration are increasingly becoming the standard in cancer care delivery.
“If you look at oncology care, I think some of the most important changes in provider payment reform are actually being led in cancer care,” said Mark McClellan, MD, PhD, director of the Health Care Innovation and Value Initiative at the Brookings Institution in Washington. “This is a place to look for what could be a model for reforms in payments that would affect other parts of our healthcare system, other specialties.”
Dr McClellan is involved in a project at the Institution which is reviewing payment reform activities in conjunction with the Center for Medicare & Medicaid Innovation. “We’re finding a lot of activity related to cancer,” he said.
Dr McClellan, who also served as the administrator for the Centers for Medicare & Medicaid Services from 2004 to 2005, said oncologists have adopted several models of care to fit their needs. Those models include clinical pathways, the patient-centered medical oncology home, bundled payments, and the oncology accountable care organization.
He added that doing all this “requires a very strong...evidence infrastructure, both on the quality of care that’s being provided and in terms of providing data to the patients and physicians and other providers involved in delivering care so they can find ways to improve on performance and understand where they are.” However, such an infrastructure has yet to be developed.
Lee Newcomer, MD, MHA, senior vice president at UnitedHealthcare, also said, “We have to think about how do we become more efficient both in the research arena and in delivery of care.”
Around the Web
Oncologists Lead on Reform, Ex CMS Head Says [Med Page Today]
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More